Prothena (PRTA) Presents At Oppenheimer 29th Annual Healthcare Conference - Slideshow

Prothena Corporate Overview March 20, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935); the design of the Phase 2 PASADENA study of prasinezumab; amounts we might receive under ...